A Single Arm Study to Evaluate the Safety and Efficiency of Azacitidine (AZA) Combination With Venetoclax and ATRA in Patients With Newly Diagnosed Acute Myeloid Leukemia
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Rate of the bone marrow complete response
研究概览
简要总结
This is a single arm study to evaluate the safety and efficiency of azacitidine (AZA) combination with venetoclax and ATRA in Patients With Newly diagnosed acute myeloid leukemia. Azacitidine, venetoclax and ATRA, may stop the growth of cancer cells, either by demethylation, by promoting cells differentiation or by killing the cells.
详细描述
This study include newly diagnosed AML patients who will accept the therapy with AZA combined with venetoclax and ATRA: (1)Inductive therapy: AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28, every 28 days for up to 2 cycles or progression; (2)Consolidate therapy:ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles or progression; (3) Maintenance therapy:ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month till progression;
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Newly diagnosed AML according to the WHO (2016) classification of acute myeloid leukemia.
- •Age ≥ 18years.
- •ECOG score: 0-
- •White blood cell count ≤ 25*10^9/L
- •Total bilirubin ≤ 3X the institutional upper limit of normal if attributable to hepatic infiltration by neoplastic disease
- •AST (SGOT) and ALT (SGPT) ≤ 3X the institutional upper limit of normal
- •Creatinine clearance ≥30ml/min
排除标准
- •Pregnancy or lactation.
- •Acute promylocytic leukemia or chronic myeloid leukemia in blast crisis.
- •Another malignant disease.
- •Uncontrolled active infection.
- •Left ventricular ejection fraction < 0.3 by echocardiography or grade III/IV cardiovascular dysfunction according to the New York Heart Association Classification.
- •Active hepatitis B or hepatitis C infection.
- •HIV infection.
- •Other commodities that the investigators considered not suitable for the enrollment.
研究组 & 干预措施
AVA（Azacitidine Combined With Venetoclax and ATRA）group
(1)Inductive therapy: AZA 75mg/m² per day for days 1-7 and venetoclax 100mg orally for day 2 , 200mg orally for day 3, 300mg orally for day4-6, 400mg orally for day7-10,ATRA 45mg/m² for day 12-28,every 28 days for up to 2 cycles or progression; (2)Consolidate therapy:ATRA 45mg/m2 per day for d1-21 ,AZA 70mg/m² per day for days 1-7, every 28 days for up to 4 cycles or progression; (3) Maintenance therapy:ATRA 45mg/m2 for d1-21 every 28 days,AZA 70mg/m² per day for days 1-7, every 3 month untill progression;
干预措施: Azacitidine Combined With Venetoclax and ATRA group (Drug)
结局指标
主要结局
Rate of the bone marrow complete response
时间窗: after completion of one induction courses (1st Induction Course is 28 days) and before starting of the 2nd cycle
Rate of the bone marrow complete response after 1 cycle of inductive therapy include Rate of the bone marrow complete response included the rate of the including Complete Remission(CR) and Complete Remission with incomplete hematologic recovery (CRi) after 1 cycle of inductive therapy
次要结局
- Event Free Survival（EFS）(2 years)
- Rate of the bone marrow complete response after 2 cycle of inductive therapy(after completion of two induction courses (1st Induction Course is 28 days) and before starting of the 1st Consolidation cycle)
- Number of adverse events(2 years)
- Minimal Residual Disease (MRD) response(after completion of two induction courses (one Course is 28 days) and before starting of the 1st Consolidation cycle)
- Overall Survival (OS)(2 years)